Curtis Carlson, MD
Internal Medicine · Raleigh, NCNPI 1336134394
Payments from drug & device makers
Across 171 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$734
- Amgen$253
- Lilly USA, LLC$247
- Johnson & Johnson$174
- Astellas Pharma US Inc$169
- Abbott$125
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $734 |
| Amgen | 18 | $253 |
| Lilly USA, LLC | 15 | $247 |
| Johnson & Johnson | 16 | $174 |
| Astellas Pharma US Inc | 11 | $169 |
| Abbott | 6 | $125 |
| Biotronik NRO, Inc. | 3 | $120 |
| Pfizer | 8 | $107 |
| Daiichi Sankyo Inc. | 5 | $86 |
| Boehringer Ingelheim | 5 | $82 |
| Merck | 5 | $76 |
| Grifols USA, LLC | 4 | $63 |
| GSK | 3 | $48 |
| AbbVie | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $33 |
| Abiomed | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Seqirus USA Inc | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Novartis | 2 | $24 |
| Dexcom, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Shionogi Inc | 1 | $18 |
| Medtronic | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Echosens North America, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| Sonex Health, Inc. | 1 | $12 |
| Insightec,inc | 1 | $11 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
How this compares
$2,725 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 200 | $232,015 |
| JardianceEmpagliflozin | 229 | $197,072 |
| OzempicSemaglutide | 164 | $163,625 |
| TrulicityDulaglutide | 55 | $77,075 |
| MounjaroTirzepatide | 61 | $63,728 |
| XareltoRivaroxaban | 31 | $48,030 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $35,297 |
| MyrbetriqMirabegron | 34 | $32,787 |
| JanuviaSitagliptin Phosphate | 24 | $30,625 |
| Repatha SureclickEvolocumab | 30 | $22,334 |
| FarxigaDapagliflozin Propanediol | 14 | $13,346 |
| Spiriva RespimatTiotropium Bromide | 11 | $9,131 |
| Rosuvastatin Calcium | 622 | $7,914 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,339 |
| BelsomraSuvorexant | 11 | $7,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $107 | $232,015200 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $82 | $206,203240 claims |
| Novo NordiskOzempic | $734 | $163,625164 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $247 | $140,803116 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $48 | $48,05667 claims |
| Johnson & JohnsonXarelto | $174 | $48,03031 claims |
| MerckJanuvia, Belsomra | $76 | $37,85035 claims |
| Astellas Pharma US IncMyrbetriq | $169 | $32,78734 claims |
| AbbVieSynthroid, Armour Thyroid | $42 | $8,21591 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Raleigh
- John RubinoRaleigh$13M
- Wayne HarperRaleigh$6.7M
- Bhakti PaulRaleigh$536K
- Clifford CurtisRaleigh$376K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.